Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
Eli Lilly and Co. and Zymeworks said Wednesday that they are expanding a cancer drug development partnership.
The companies announced a partnership in January but did not disclose terms. Without explaining the initial terms of the partnership, the companies said Zymeworks could get an additional $375 million in milestones and other payments. It will also receive royalties on sales of any approved drugs, and Lilly will make an investment in Zymeworks.
The companies say they will study "bi-specific antibodies," or drugs that use the immune system to treat diseases by targeting two different proteins.
Shares in Indianapolis-based Lilly were unchanged at $64.68 on Wednesday.
Zymeworks is a privately held Canadian company.
Please enable JavaScript to view this content.